MarketBeat
22 Nov 2026, 15:12 UTC · 1h ago
Neurocrine Biosciences Sees INGREZZA Growth, Awaits Key 2027 Trial Results
Impact · against what's priced in
The news is largely neutral to slightly positive for NBIX as strong Ingrezza performance and Medicare clarity confirm the current baseline, while CRENESSITY's rapid ramp challenges the market's skepticism regarding its growth. The 2027 pipeline catalysts remain optionality that the market is not yet paying for.
- NBIX+0.30
Challenges what's priced in
- The price assumes
Crenessity's rapid adoption for congenital adrenal hyperplasia becoming a meaningful second pillar of growth





